{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:02:33Z","timestamp":1791957753459,"version":"4.3.4"},"reference-count":41,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21DA053324"],"award-info":[{"award-number":["R21DA053324"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Prim Care Community Health"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The COVID-19 pandemic catalyzed a rapid shift in healthcare delivery towards telehealth services, impacting patient care, including opioid use disorder (OUD) treatment. Regulatory changes eliminated the in-person evaluation requirement for buprenorphine treatment, encouraging adoption of telehealth. This study focused on understanding experiences of primary care providers in predominantly rural areas who used telehealth for OUD treatment during the pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Semi-structured interviews were conducted with 22 primary care providers. Participants practiced in 13 rural and 9 urban counties in Kentucky and Arkansas. Data were analyzed using conventional content analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The pandemic significantly impacted healthcare delivery. While telehealth was integrated for behavioral health counseling, in-person visits remained crucial, especially for urine drug screenings. Telehealth experiences varied, with some facing technology issues, while others found it efficient. Telehealth proved valuable for behavioral health counseling and sustaining relationships with established patients. Patients with OUD faced unique challenges, including housing, internet, transportation, and counseling needs. Stigma surrounding OUD affected clinical relationships. Building strong patient-provider relationships emerged as a central theme, emphasizing the value of face-to-face interactions. Regarding buprenorphine training, most found waiver training helpful but lacked formal education.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This research offers vital guidance for improving OUD treatment services, especially in rural areas during crises like the COVID-19 pandemic. It highlights telehealth\u2019s value as a tool while acknowledging its limitations. The study underscores the significance of strong patient-provider relationships, the importance of reducing stigma, and the potential for training programs to elevate quality of care in OUD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/21501319241246359","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T02:47:40Z","timestamp":1712803660000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary Care Providers\u2019 Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-7866","authenticated-orcid":false,"given":"Sarah Alexandra","family":"Marshall","sequence":"first","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachan E.","family":"Siebenmorgen","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Youngen","sequence":"additional","affiliation":[{"name":"University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5276-2005","authenticated-orcid":false,"given":"Tyrone","family":"Borders","sequence":"additional","affiliation":[{"name":"University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolas","family":"Zaller","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"bibr1-21501319241246359","unstructured":"CDC. Drug Overdose Deaths. Centers for Disease Control and Prevention. Updated August 22, 2023. Accessed February 28, 2024. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html"},{"key":"bibr2-21501319241246359","volume-title":"Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report","author":"Ringeisen H","year":"2023"},{"key":"bibr3-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"bibr4-21501319241246359","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Methadone. Updated March 29, 2024. Accessed April 5, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/medications-counseling-related-conditions\/methadone"},{"key":"bibr5-21501319241246359","unstructured":"SAMHSA. Buprenorphine. Updated March 28, 2024. Accessed April 5, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/medications-counseling-related-conditions\/buprenorphine"},{"key":"bibr6-21501319241246359","unstructured":"SAMHSA. Waiver Eliminaton (MAT Act). Updated October 10, 2023. Accessed February, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act"},{"key":"bibr7-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12438"},{"key":"bibr8-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12570"},{"key":"bibr9-21501319241246359","unstructured":"DEA. COVID-19 FAQ. Accessed April 5, 2024. https:\/\/www.deadiversion.usdoj.gov\/faq\/coronavirus-faq.html"},{"key":"bibr10-21501319241246359","unstructured":"SAMHSA. FAQ: Provisions of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency. March 19, 2020. Accessed February 28, 2024. https:\/\/www.nabh.org\/wp-content\/uploads\/2020\/03\/faqs-for-oud-prescribing-and-dispensing.pdf"},{"key":"bibr11-21501319241246359","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1210"},{"key":"bibr12-21501319241246359","unstructured":"HHS. Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19. Updated January 20, 2021. Accessed February 28, 2024. https:\/\/www.hhs.gov\/hipaa\/for-professionals\/special-topics\/emergency-preparedness\/notification-enforcement-discretion-telehealth\/index.html"},{"key":"bibr13-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07174-w"},{"key":"bibr14-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108783"},{"key":"bibr15-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000948"},{"key":"bibr16-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.00859"},{"key":"bibr17-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2012.07.006"},{"key":"bibr18-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109933"},{"key":"bibr19-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2018.05145"},{"key":"bibr20-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.01622"},{"key":"bibr21-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12548"},{"key":"bibr22-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12760"},{"key":"bibr23-21501319241246359","unstructured":"CDC. Drug Overdose Mortality by State. Centers for Disease Control and Prevention. Updated March 1, 2022. Accessed February 28, 2024. https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm"},{"key":"bibr24-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103836"},{"key":"bibr25-21501319241246359","unstructured":"OMB. 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas. June 28, 2010. Accessed April 5, 2024. https:\/\/www.federalregister.gov\/documents\/2010\/06\/28\/2010-15605\/2010-standards-for-delineating-metropolitan-and-micropolitan-statistical-areas"},{"key":"bibr26-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12683"},{"key":"bibr27-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1177\/160940691201100409"},{"key":"bibr28-21501319241246359","volume-title":"Three Approaches to Qualitative Content Analysis","author":"Hsieh H-F","year":"2007"},{"key":"bibr29-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1080\/16066350500102237"},{"key":"bibr30-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001156"},{"key":"bibr31-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2022.2064509"},{"key":"bibr32-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06436-3"},{"key":"bibr33-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2284"},{"key":"bibr34-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06969-1"},{"key":"bibr35-21501319241246359","unstructured":"SAMHSA. Waiver Elimination (MAT Act). U.S. Department of Health & Human Services. Updated October 10, 2023. Accessed February 28\ufeff, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act"},{"key":"bibr36-21501319241246359","first-page":"104","volume":"2016","author":"DeVoe JE","journal-title":"Ann Fam Med"},{"key":"bibr37-21501319241246359","author":"Magnan S.","journal-title":"NAM Perspect"},{"key":"bibr38-21501319241246359","doi-asserted-by":"publisher","DOI":"10.31478\/202106c"},{"key":"bibr39-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209133"},{"key":"bibr40-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2021.1975749"},{"key":"bibr41-21501319241246359","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.2018.0036"}],"container-title":["Journal of Primary Care &amp; Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319241246359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21501319241246359","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319241246359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:22:29Z","timestamp":1777508549000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21501319241246359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"alternative-id":["10.1177\/21501319241246359"],"URL":"https:\/\/doi.org\/10.1177\/21501319241246359","relation":{},"ISSN":["2150-1319","2150-1327"],"issn-type":[{"value":"2150-1319","type":"print"},{"value":"2150-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"21501319241246359"}}